CD4 and melanoma: The clinical significance of this subdivision of CD4+CD25+ cells was highlighted in an immunotherapy study with malignant melanoma patients [17]: the application of an anti-CD25 antibody proved to be too unspecific to only delete T regulatory cells, since it also eliminated effector cells, leading to reduced instead of enhanced immune responses.